Carrier-free nanoparticles based on chemotherapy-gene therapy synergy and preparation and anti-liver cancer application thereof
The invention belongs to the technical field of biological medicines, and particularly relates to carrier-free nanoparticles based on chemotherapy-gene therapy synergy and preparation and anti-liver cancer application thereof. The carrier-free nanoparticle comprises an inner core and a shell coated outside the inner core, the inner core takes protamine sulfate as an auxiliary agent, ursolic acid, sorafenib and a CRISPR (clustered regularly interspaced short palindromic repeats) system Cas9/RNP compound are jointly assembled through multiple coordination, pi-pi accumulation, static and hydrophobic acting force to form the inner core, and the shell is HepG2 cell membrane; wherein the Cas9/RNP compound of the CRISPR system comprises a Cas9 protein and sgRNA (small guide ribonucleic acid) of a specific targeting PD-L1 gene. The carrier-free nanoparticles can be specifically accumulated at a liver cancer part through a cell membrane homologous recognition effect, and can reach into a cell nucleus for gene editing under the action of a gene drug nuclear localization sequence, so that a chemotherapy-gene therapy combined anti-liver cancer effect is realized, and the carrier-free nanoparticles have a remarkable inhibition effect on the growth of liver cancer; the compound has a wide application prospect in preparation of anti-liver cancer drugs..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 08. Sept. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
SHAO JINGWEI [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-09-08, Last update posted on www.tib.eu: 2023-12-19, Last updated: 2023-12-22 |
|---|
| Patentnummer: |
CN116712407 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA018694446 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA018694446 | ||
| 003 | DE-627 | ||
| 005 | 20231222113223.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231215s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA018694446 | ||
| 035 | |a (EPA)CN116712407 | ||
| 035 | |a (EPA)87873020 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a SHAO JINGWEI |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Carrier-free nanoparticles based on chemotherapy-gene therapy synergy and preparation and anti-liver cancer application thereof |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-09-08, Last update posted on www.tib.eu: 2023-12-19, Last updated: 2023-12-22 | ||
| 520 | |a The invention belongs to the technical field of biological medicines, and particularly relates to carrier-free nanoparticles based on chemotherapy-gene therapy synergy and preparation and anti-liver cancer application thereof. The carrier-free nanoparticle comprises an inner core and a shell coated outside the inner core, the inner core takes protamine sulfate as an auxiliary agent, ursolic acid, sorafenib and a CRISPR (clustered regularly interspaced short palindromic repeats) system Cas9/RNP compound are jointly assembled through multiple coordination, pi-pi accumulation, static and hydrophobic acting force to form the inner core, and the shell is HepG2 cell membrane; wherein the Cas9/RNP compound of the CRISPR system comprises a Cas9 protein and sgRNA (small guide ribonucleic acid) of a specific targeting PD-L1 gene. The carrier-free nanoparticles can be specifically accumulated at a liver cancer part through a cell membrane homologous recognition effect, and can reach into a cell nucleus for gene editing under the action of a gene drug nuclear localization sequence, so that a chemotherapy-gene therapy combined anti-liver cancer effect is realized, and the carrier-free nanoparticles have a remarkable inhibition effect on the growth of liver cancer; the compound has a wide application prospect in preparation of anti-liver cancer drugs. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a ZHANG BINGCHEN |4 aut | |
| 700 | 0 | |a LI LINYAN |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 08. Sept. |
| 773 | 1 | 8 | |g year:2023 |g day:08 |g month:09 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/87873020/publication/CN116712407A1?q=CN116712407 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 08 |c 09 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 08 |c 09 | ||